이식형 루프 레코더 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the implantable loop recorder market size is expected to grow from USD 1.37 billion in 2025 to USD 1.49 billion in 2026 and is forecasted to reach USD 2.29 billion by 2031 at 8.94% CAGR over 2026-2031.

This report is Segmented by Indication (Syncope/Presyncope, Atrial Fibrillation Detection, Cryptogenic Stroke and Palpitations & Other Arrhythmias), End Users (Hospitals, Cardiac Centers, Ambulatory Surgical Centers Home-Based & Remote Monitoring Programs), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Implantable Loop Recorders Market Trends and Insights

Rising Incidence of Atrial Fibrillation & Cryptogenic Stroke

Expanding lifetime risk of atrial fibrillation from 24.2% to 30.9% across developed regions intensifies demand for prolonged cardiac surveillance. Implantable loop recorders detect previously hidden atrial fibrillation in 19.5% of cryptogenic stroke cases within national registries, enabling earlier secondary prevention through anticoagulation. Traditional 24-hour Holter studies miss many paroxysmal events, whereas median detection emerges 7.9 months after device insertion, underscoring the clinical value of continuous monitoring. As a result, neurologists increasingly collaborate with electrophysiologists to implant recorders in stroke units before discharge to curtail recurrent events. This epidemiological momentum underpins long-run adoption across both hospital and outpatient settings.

Growing Preference for Long-Term Ambulatory Rhythm Monitoring

Diagnostic yield rises markedly when cardiac surveillance extends from 24 hours to 7 days, amplifying premature ventricular contraction quantification accuracy. Extended monitoring devices now represent 40% of connected cardiac monitors in US clinics, while mobile telemetry contributes another 20%, indicating significant displacement of brief Holter studies. Physicians value higher arrhythmia detection in low-symptom patients, which translates into earlier therapy initiation and fewer unplanned admissions. Health systems also document economic benefits through reduced duplicate testing and shorter diagnostic journeys. These advantages align with payer incentives that reimburse single-procedure implant and multi-year data review, accelerating the transition toward continuous monitoring modalities.

High Device & Implantation Costs

Procedure fees remain a prominent barrier, with Australian reimbursement schedules listing AUD 175.75 (USD 117.8) for insertion alone, while device prices range from USD 11,329 upward for AI-enabled systems. Budget pressures intensify as US physician fee schedules project 2.93% rate cuts in 2025, squeezing hospital margins . Many emerging markets allocate scarce cardiac funds to basic revascularization, leaving limited capacity for premium recorders despite rising cardiovascular incidence. Vendors attempt to counter pricing sensitivity through leasing models and performance-based contracts but affordability hurdles still temper adoption pace outside high-income regions.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advances in Miniaturization & Bluetooth Telemetry
2. AI-Enabled Predictive Analytics for Asymptomatic Arrhythmia
3. Data-Management Burden on Electrophysiology Clinics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Syncope/Presyncope retained 45.98% of the implantable loop recorder market share in 2025, driven by its high diagnostic yield over conventional tilt-table or Holter tests. Physicians consider continuous rhythm capture the gold standard when unexplained fainting threatens driving privileges or occupational safety. Implant data reveal actionable arrhythmias in up to 33% of syncope cases within 12 months, enabling pacemaker or ablation interventions that cut readmissions. The implantable loop recorder market size for syncope applications is projected to advance steadily as aging populations raise incidence of neuro-cardiogenic events.

Cryptogenic Stroke is advancing at a 10.59% CAGR, outpacing other indications through compelling evidence that 28.2% of implanted patients experience covert atrial fibrillation within three years. Stroke specialists increasingly embed recorders during index admission to accelerate anticoagulation decisions, a practice supported by updated neurology guidelines. Payers acknowledge cost offsets from avoided recurrent strokes, facilitating broader coverage. Over the forecast horizon, stroke-led growth will continue to elevate total implant volumes, narrowing the share gap with syncope.

Atrial Fibrillation Detection outside the stroke setting remains a sizeable niche where recorders confirm symptomatic palpitations when surface ECG fails. Post-procedure monitoring after pulmonary vein isolation also leverages multi-year visibility to gauge ablation success. Palpitations & Other Arrhythmias benefit from extended capture of ventricular ectopy and inherited rhythm disorders in younger cohorts who reject bulky external devices. Collectively, evolving evidence keeps all indications in positive territory, sustaining balanced portfolio demand for manufacturers.

Complete Report Scope:

• By Indication
  • Syncope/Presyncope
  • Atrial Fibrillation Detection
  • Cryptogenic Stroke
  • Palpitations & Other Arrhythmias
• By End-User
  • Hospitals
  • Cardiac Centers & Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Home-based & Remote Monitoring Programs
• By Region
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America accounted for 46.92% of worldwide revenue in 2025, supported by Medicare National Coverage Determinations that reimburse implants across syncope, stroke, and atrial fibrillation indications . Extensive cardiology infrastructure, high public awareness, and broad telehealth acceptance sustain volume growth. Purchasing consortia negotiate bulk pricing, but the implantable loop recorder market remains value-oriented due to outcome-based payment incentives that reward stroke avoidance and readmission reduction.

Europe maintains consistent expansion through universal healthcare systems that emphasize preventive cardiology. Germany, the United Kingdom, and France anchor regional demand with large electrophysiology capacities and harmonized device approvals under MDR. Cross-country initiatives share registry data, accelerating evidence generation and standardizing care protocols. Southern and Eastern European states adopt implantable recorders more gradually as reimbursement parity evolves, but overall penetration keeps rising alongside aging demographics.

Asia-Pacific shows the highest trajectory with a 10.62% CAGR through 2031. Urban hospitals in China and Japan rapidly integrate miniaturized recorders into stroke units, leveraging national policies that prioritize non-communicable disease management. India's tier-one cities display growing adoption among middle-class consumers seeking private cardiology services. Government insurance schemes in several Southeast Asian nations commence pilot reimbursements, encouraging broader clinical use. Despite heterogeneous health financing and physician distribution, cumulative regional demand scales quickly, reflecting large patient bases and escalating cardiovascular disease prevalence. South America and the Middle East & Africa observe early-stage uptake where tertiary centers spearhead technology introduction, yet economic and infrastructure constraints temper near-term share.

1. Medtronic
2. Abbott Laboratories
3. BIOTRONIK
4. Boston Scientific
5. Angel Medical Systems
6. iRhythm Technologies
7. MicroPort
8. Vectorious Medical
9. LivaNova
10. Koninklijke Philips
11. Bardy Diagnostics
12. Eko Devices

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence of Atrial Fibrillation & Cryptogenic Stroke
  • 4.2.2 Growing Preference for Long-Term Ambulatory Rhythm Monitoring
  • 4.2.3 Technological Advances in Miniaturization & Bluetooth Telemetry
  • 4.2.4 Favorable Reimbursement Expansions in the US & EU
  • 4.2.5 AI-Enabled Predictive Analytics for Asymptomatic Arrhythmia
  • 4.2.6 CMS Bundled Stroke Payment Pushing Hospitals Toward IRLs
• 4.3 Market Restraints
  • 4.3.1 High Device & Implantation Costs
  • 4.3.2 Risk of Infection, Pocket Erosion & False-Positive Alerts
  • 4.3.3 Data-Management Burden on Electrophysiology Clinics
  • 4.3.4 Increasing Cybersecurity / Patient-Privacy Concerns
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Indication
  • 5.1.1 Syncope/Presyncope
  • 5.1.2 Atrial Fibrillation Detection
  • 5.1.3 Cryptogenic Stroke
  • 5.1.4 Palpitations & Other Arrhythmias
• 5.2 By End-User
  • 5.2.1 Hospitals
  • 5.2.2 Cardiac Centers & Clinics
  • 5.2.3 Ambulatory Surgical Centers (ASCs)
  • 5.2.4 Home-based & Remote Monitoring Programs
• 5.3 By Region
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 South Korea
    • 5.3.3.5 Australia
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 South America
    • 5.3.4.1 Brazil
    • 5.3.4.2 Argentina
    • 5.3.4.3 Rest of South America
  • 5.3.5 Middle East and Africa
    • 5.3.5.1 GCC
    • 5.3.5.2 South Africa
    • 5.3.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Competitive Benchmarking
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Medtronic plc
  • 6.4.2 Abbott Laboratories
  • 6.4.3 Biotronik SE & Co. KG
  • 6.4.4 Boston Scientific Corp.
  • 6.4.5 Angel Medical Systems
  • 6.4.6 iRhythm Technologies
  • 6.4.7 MicroPort Scientific
  • 6.4.8 Vectorious Medical
  • 6.4.9 LivaNova PLC
  • 6.4.10 Philips Healthcare
  • 6.4.11 Bardy Diagnostics
  • 6.4.12 Eko Devices

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment